Trial · NCT02011945
Results by group170
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 170
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Dose Limiting Toxicities (DLT) | Dasatinib Only | 0 | Number of Incidence | ||
| Incidence of Dose Limiting Toxicities (DLT) | Dose Level 1 | 0 | Number of Incidence | ||
| Incidence of Dose Limiting Toxicities (DLT) | Dose Level 2 | 0 | Number of Incidence | ||
| Incidence of Adverse Events (AEs) | Dose Level 1 | CML-CP, No Prior dasatinib treatment | 1 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dose Level 2 | CML-CP, No Prior dasatinib treatment | 2 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dasatinib Only | CML-CP, Prior dasatinib treatment | 1 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dose Level 1 | CML-CP, Prior dasatinib treatment | 8 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dose Level 2 | CML-CP, Prior dasatinib treatment | 11 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dose Level 1 | CML-AP participants | 4 | Number of Adverse Events | |
| Incidence of Adverse Events (AEs) | Dose Level 2 | CML-AP participants | 3 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 1 | CML-CP, No Prior dasatinib treatment | 0 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 2 | CML-CP, No Prior dasatinib treatment | 2 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dasatinib Only | CML-CP, Prior dasatinib treatment | 0 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 1 | CML-CP, Prior dasatinib treatment | 3 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 2 | CML-CP, Prior dasatinib treatment | 4 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 1 | CML-AP participants | 4 | Number of Adverse Events | |
| Incidence of Serious Adverse Events (SAEs) | Dose Level 2 | CML-AP participants | 2 | Number of Adverse Events | |
| Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology | Dasatinib Only | Hemoglobin | 0 | Participants | |
| Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology | Dose Level 1 | Hemoglobin | 2 | Participants | |
| Incidence of Change From Baseline in Clinical Laboratory Tests: Hematology | Dose Level 2 | Hemoglobin | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02011945/results